Current and Future Trends in Treatment of Severe Retinopathy of Prematurity

David K. Wallace, Katherine Y. Wu

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Treatment for retinopathy of prematurity (ROP) is indicated when type 1 disease is present. The Early Treatment for Retinopathy of Prematurity (ETROP) clinical trial established that laser treatment of severe ROP has a high rate of visual and anatomic success. Recently, anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab have been used in lieu of or in addition to laser treatment. Results are promising, but long-term outcomes and systemic side effects are unknown. Future studies are needed to determine whether anti-VEGF treatment is superior to laser and, if so, which drug and dose are safe and effective.

Original languageEnglish (US)
Pages (from-to)297-310
Number of pages14
JournalClinics in Perinatology
Volume40
Issue number2
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Retinopathy of Prematurity
Lasers
Vascular Endothelial Growth Factor A
Pharmaceutical Preparations
Clinical Trials

Keywords

  • Bevacizumab
  • Clinical trials
  • Laser photocoagulation
  • Retinopathy of prematurity
  • Side effects
  • Type 1

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Current and Future Trends in Treatment of Severe Retinopathy of Prematurity. / Wallace, David K.; Wu, Katherine Y.

In: Clinics in Perinatology, Vol. 40, No. 2, 01.06.2013, p. 297-310.

Research output: Contribution to journalReview article

@article{8df01e7077ad4e57ab3ced283bc3dc66,
title = "Current and Future Trends in Treatment of Severe Retinopathy of Prematurity",
abstract = "Treatment for retinopathy of prematurity (ROP) is indicated when type 1 disease is present. The Early Treatment for Retinopathy of Prematurity (ETROP) clinical trial established that laser treatment of severe ROP has a high rate of visual and anatomic success. Recently, anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab have been used in lieu of or in addition to laser treatment. Results are promising, but long-term outcomes and systemic side effects are unknown. Future studies are needed to determine whether anti-VEGF treatment is superior to laser and, if so, which drug and dose are safe and effective.",
keywords = "Bevacizumab, Clinical trials, Laser photocoagulation, Retinopathy of prematurity, Side effects, Type 1",
author = "Wallace, {David K.} and Wu, {Katherine Y.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1016/j.clp.2013.02.005",
language = "English (US)",
volume = "40",
pages = "297--310",
journal = "Clinics in Perinatology",
issn = "0095-5108",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Current and Future Trends in Treatment of Severe Retinopathy of Prematurity

AU - Wallace, David K.

AU - Wu, Katherine Y.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Treatment for retinopathy of prematurity (ROP) is indicated when type 1 disease is present. The Early Treatment for Retinopathy of Prematurity (ETROP) clinical trial established that laser treatment of severe ROP has a high rate of visual and anatomic success. Recently, anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab have been used in lieu of or in addition to laser treatment. Results are promising, but long-term outcomes and systemic side effects are unknown. Future studies are needed to determine whether anti-VEGF treatment is superior to laser and, if so, which drug and dose are safe and effective.

AB - Treatment for retinopathy of prematurity (ROP) is indicated when type 1 disease is present. The Early Treatment for Retinopathy of Prematurity (ETROP) clinical trial established that laser treatment of severe ROP has a high rate of visual and anatomic success. Recently, anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab have been used in lieu of or in addition to laser treatment. Results are promising, but long-term outcomes and systemic side effects are unknown. Future studies are needed to determine whether anti-VEGF treatment is superior to laser and, if so, which drug and dose are safe and effective.

KW - Bevacizumab

KW - Clinical trials

KW - Laser photocoagulation

KW - Retinopathy of prematurity

KW - Side effects

KW - Type 1

UR - http://www.scopus.com/inward/record.url?scp=84878167722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878167722&partnerID=8YFLogxK

U2 - 10.1016/j.clp.2013.02.005

DO - 10.1016/j.clp.2013.02.005

M3 - Review article

C2 - 23719311

AN - SCOPUS:84878167722

VL - 40

SP - 297

EP - 310

JO - Clinics in Perinatology

JF - Clinics in Perinatology

SN - 0095-5108

IS - 2

ER -